Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|February 1, 2024
Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical TrialChristine A Shaw, Runa Mithani, Archana Kapoor, et al.
Pediatrics|May 13, 2024
Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive ChildrenSabine Schnyder Ghamloush, Brandon Essink, Bo Hu, et al.
Journal of Virology|August 1, 2014
A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopesKurt A Swanson, Kara Balabanis, Yuhong Xie, et al.
Vaccine|November 17, 2012
The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced diseaseChristine A Shaw, Jean-Rene Galarneau, Kathryn E Bowenkamp, et al.
Human Vaccines & Immunotherapeutics|September 15, 2025
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 monthsSabine Schnyder Ghamloush, Sue Fanning, Brandon Essink, et al.
Nature Medicine|March 19, 2025
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trialAmanda K Rudman Spergel, Jintanat Ananworanich, Ruiting Guo, et al.
The Journal of Infectious Diseases|February 22, 2024
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older AdultsChristine A Shaw, Brandon Essink, Charles Harper, et al.
Respiratory Investigation|September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trialDavid Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
Nature Communications|July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trialChong Ma, Jiejun Du, Lan Lan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 YearsJaya Goswami, Jose F Cardona, Jorge Caso, et al.
Pageof 4